• Average baseline A1C ∼ 8.0%
  • Average baseline fasting blood sugar ∼ 172 mg/dl
  • Reference [11]
Alogliptin (Alo) monotherapy, 26-week trial
Placebo
(N=63)
Alo 25 mg once daily
(N=128)
HgA1C (%)
(change from baseline)
0% -0.6%
Fasting blood sugar (mg/dl)
(change from baseline)
+11 -16

  • Average baseline A1C ∼ 8.0%
  • Average baseline fasting blood sugar ∼ 176 mg/dl
  • Metformin dose was ≥ 1500 mg/day
  • Reference [11]
Alogliptin (Alo) added to metformin, 26-week trial
Placebo + metformin
(N=103)
Alo 25 mg once daily + metformin
(N=203)
HgA1C (%)
(change from baseline)
-0.1% -0.6%
Fasting blood sugar (mg/dl)
(change from baseline)
0 -17

  • Average baseline A1C - 8.0%
  • Average baseline fasting blood sugar ∼ 165 mg/dl
  • Reference [3]
Linagliptin (Lin) monotherapy, 24-week trial
Placebo
(N=163)
Lin 5 mg once daily
(N=333)
HgA1C (%)
(change from baseline)
+0.3% -0.4%
Fasting blood sugar (mg/dl)
(change from baseline)
+15 -9

  • Average baseline A1C ∼ 8.0%
  • Average baseline fasting blood sugar ∼ 166 mg/dl
  • Metformin dose was ≥ 1500 mg/day
  • Reference [3]
Linagliptin (Lin) added to metformin, 24-week trial
Placebo + metformin
(N=175)
Lin 5 mg once daily + metformin
(N=513)
HgA1C (%)
(change from baseline)
+0.15% -0.5%
Fasting blood sugar (mg/dl)
(change from baseline)
+11 -11

  • Average baseline A1C ∼ 7.9%
  • Average baseline fasting blood sugar ∼ 174 mg/dl
  • Reference [2]
Saxagliptin (Sax) monotherapy, 24-week trial
Placebo
(N=95)
Sax 2.5 mg once daily
(N=102)
Sax 5 mg once daily
(N=106)
HgA1C (%)
(change from baseline)
+0.2% -0.4% -0.5%
Fasting blood sugar (mg/dl)
(change from baseline)
+6 -15 -9

  • Average baseline A1C - 8.1%
  • Average baseline fasting blood sugar ∼ 175 mg/dl
  • Metformin dose was ≥ 1500 mg/day
  • Reference [2]
Saxagliptin (Sax) added to metformin (met), 24-week trial
Placebo + met
(N=179)
Sax 2.5 mg once daily + met
(N=192)
Sax 5 mg once daily + met
(N=191)
HgA1C (%)
(change from baseline)
+0.1% -0.6% -0.7%
Fasting blood sugar (mg/dl)
(change from baseline)
+1 -14 -22

  • Average baseline A1C - 8.0%
  • Average baseline fasting blood sugar ∼ 173 mg/dl
  • Reference [1]
Sitagliptin (Sit) monotherapy, 24-week trial
Placebo
(N=244)
Sit 100 mg once daily
(N=229)
HgA1C (%)
(change from baseline)
+0.2% -0.6%
Fasting blood sugar (mg/dl)
(change from baseline)
+5 -12

  • Average baseline A1C - 8%
  • Average baseline fasting blood sugar ∼ 172 mg/dl
  • Metformin dose was ≥ 1500 mg/day
  • Reference [1]
Sitagliptin (Sit) added to metformin, 24-week trial
Placebo
+ metformin
(N=224)
Sit 100 mg once daily
+ metformin
(N=453)
HgA1C (%)
(change from baseline)
0% -0.7%
Fasting blood sugar (mg/dl)
(change from baseline)
+9 -17